Harvest Health & Recreation Inc. Reports Second Quarter 2020 Financial Results

Harvest Health & Recreation Inc. Reports Second Quarter 2020 Financial Results

PHOENIX, Aug. 11, 2020 /CNW/ — * Second quarter revenue was $55. Aug 11, 2020 (The Expresswire) —
Report Title:Global Luxury Bag Market Insights, Forecast to 2025 Global Luxury Bag Market Report Focuses on Industry chain… IBIO stock is rewarding investors who bet on its unique approach to a Covid-19 vaccine. But now, iBio needs to deliver substance. After news of a massive federal loan caused Eastman Kodak’s stock to skyrocket, a company insider donated millions of shares to a religious nonprofit for which he has served as president. On July 29, the peak of Kodak’s recent 2,757% stock surge, a member of the company’s board of directors, George Karfunkel, and his wife A late slide in big technology companies left indexes broadly lower on Wall Street Tuesday, erasing an early gain and breaking a seven-day winning streak for the S&P 500

PHOENIX, Aug. 11, 2020 /CNW/ —

Harvest Health & Recreation, Inc. Logo (PRNewsfoto/Harvest Health & Recreation...)

  • Second quarter revenue was $55.7 million, up 109% from the second quarter 2019 and 26% sequentially

  • Second quarter adjusted EBITDA was $4.1 million compared to ($3.6) million in the first quarter of 2020

  • 2020 Revenue target increased to $215-220 million, up from $200 million

Harvest Health & Recreation Inc. (CSE: HARV, OTCQX: HRVSF), a vertically integrated cannabis company and multi-state operator in the U.S., today reported its financial and operating results for the second quarter 2020. All financial information is provided in U.S. dollars unless otherwise indicated.

Second Quarter 2020 Financial Results

  • Total revenue in the second quarter was $55.7 million, an increase of 109% from $26.6 million in the second quarter of 2019 and up 26% compared to $44.2 million in the first quarter of 2020.

  • Gross profit excluding biological adjustments in the second quarter was $23.4 million, compared to $6.7 million in the second quarter of 2019 and $18.1 million in the first quarter of 2020.

  • Gross profit margin excluding biological adjustments in the second quarter was 42.1% compared to 25.1% in the second quarter of 2019 and 41.0% in the first quarter of 2020.

  • Net loss was $18.3 million for the second quarter compared to net loss of $25.5 million in the second quarter of 2019 and $20.0 million for the first quarter 2020. 

  • Adjusted EBITDA excluding biological adjustments in the second quarter was $4.1 million compared to ($12.4) million in the second quarter of 2019 and ($3.6) million in the first quarter of 2020.

Please see the supplemental information regarding unaudited results and Non-IFRS Financial Measures at the end of this press release.

Second Quarter 2020 Business Highlights

  • Harvest announced the appointment of Deborah Keeley as Chief Financial Officer on June 22, 2020.  

  • Harvest completed the initial closing of the divestment of eight retail assets in California to Hightimes Holding Corp. for consideration of $61.5 million, consisting of $1.5 million in cash and $60.0 million in Series A Preferred Stock.     

  • As of June 30, 2020, Harvest owned, operated, or managed 35 retail locations in seven states, including 14 open dispensaries in Arizona. Harvest owned and operated dispensaries exclude retail locations serviced through Interurban.

  • As of June 30, 2020, Harvest no longer meets the definition of “foreign private issuer” under United States securities laws as more than 50% of Harvest’s issued and outstanding shares were directly or indirectly owned by shareholders of record domiciled in the United States.  As a result, Harvest will be deemed a U.S. domestic issuer under United States securities laws and will be subject to SEC reporting requirements applicable to U.S. domestic companies no later than January 1, 2021. These U.S. reporting requirements will require Harvest’s financial statements and financial data to be presented under U.S. Generally Acceptable Accounting Principles.     

Outlook
Harvest is increasing its full year 2020 revenue target to $215-220 million, up from the prior target of approximately $200 million. Harvest achieved positive adjusted EBITDA during the second quarter, ahead of the prior guidance of achievement during the second half of 2020. Forecasts assume no meaningful impacts or disruptions to our operations as a result of the COVID-19 pandemic.           

Management Commentary
“Our improved financial results during the second quarter demonstrate continued progress toward our primary goal of returning to profitability through revenue growth, cost reduction measures and investments in core markets Arizona, Florida, Maryland, and Pennsylvania,” said Chief Executive Officer Steve White. “We are continuing to build on this positive momentum as we execute on our plan.”

Conference Call & Webcast
Harvest Health and Recreation Inc. will host a conference call and audio webcast with Chief Executive Officer Steve White and Chief Financial Officer Deborah Keeley, Tuesday August 11, 2020 at 5:00 PM Eastern Time.

Registration for this event is required. Please use this link to register:
http://www.directeventreg.com/registration/event/6799406

Following registration, an email confirmation will be sent including dial in details and unique conference call codes. Registration will remain open during the call however we recommend advance registration to access the event.    

Second quarter results will be available at:
https://investor.harvesthoc.com/financials/default.aspx

The live conference call webcast and replay will be available at:
https://investor.harvesthoc.com/financials/default.aspx

HARVEST HEALTH & RECREATION INC.

Interim Unaudited Condensed Consolidated Statements of Financial Position

June 30, 2020 and December 31, 2019

(Amounts expressed in thousands of United States dollars) 

June 30,

2020

December 31,

2019

ASSETS

Current assets:

Cash and cash equivalents

$

61,668

$

22,685

Restricted cash

8,000

8,000

Accounts receivable, net

17,782

12,147

Notes receivable, current portion

47,705

51,349

Biological assets

21,299

8,057

Inventory, net

31,732

28,774

Other current assets

6,866

4,788

Total current assets

195,052

135,800

Notes receivable, net of current portion

39,002

34,430

Property, plant and equipment, net

157,530

149,867

Right-of-use asset, net

55,331

56,955

Intangibles assets, net

233,535

159,209

Corporate investments

19,091

Acquisition deposits

528

3,645

Goodwill

111,459

84,596

Assets held for sale

5,332

2,443

Other assets

17,900

8,619

TOTAL ASSETS

$

834,760

$

635,564

LIABILITIES AND STOCKHOLDERS’ EQUITY

LIABILITIES

Current liabilities:

Accounts payable

$

6,478

$

6,969

Other current liabilities

23,318

21,944

Contingent consideration, current portion

15,904

13,764

Income tax payable

5,644

5,310

Lease liability, current portion

8,501

2,885

Notes payable, current portion

32,711

8,395

Total current liabilities

92,556

59,267

Notes payable, net of current portion

257,549

202,619

Lease liability, net of current portion

49,410

54,621

Deferred tax liability

48,990

28,587

Contingent consideration, net of current portion

1,108

16,249

Other long-term liabilities

480

179

TOTAL LIABILITIES

450,093

361,522

STOCKHOLDERS’ EQUITY

Capital stock

651,505

505,709

Accumulated deficit

(273,623)

(235,348)

Stockholders’ equity attributed to Harvest Health & Recreation Inc.

377,882

270,361

Non-controlling interest

6,785

3,681

TOTAL STOCKHOLDERS’ EQUITY

384,667

274,042

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

834,760

$

635,564

HARVEST HEALTH & RECREATION INC.

Interim Unaudited Condensed Consolidated Statements of Operations

Three and Six Months Ended June 30, 2020 and 2019

(Amounts expressed in thousands of United States dollars, except share or per share data)

For the three months ended June 30,

For the six months ended June 30,

2020

2019

2020

2019

Revenue, net of discounts

$

55,669

$

26,596

$

99,905

$

45,836

Cost of goods sold

(32,246)

(19,915)

(58,332)

(31,250)

Gross profit before biological asset adjustments

23,423

6,681

41,573

14,586

Realized fair value amounts included in inventory sold

(20,134)

(7,740)

(29,227)

(13,475)

Unrealized fair value gain on growth of biological assets

27,055

13,075

39,873

18,847

Gross profit

30,344

12,016

52,219

19,958

Expenses

General and administrative

21,498

21,764

45,135

40,150

Sales and marketing

1,246

2,053

2,523

3,642

Share-based compensation

3,276

8,094

17,080

11,397

Depreciation and amortization

3,520

1,600

6,977

3,093

Total expenses

29,540

33,511

71,715

58,282

Operating income (loss)

804

(21,495)

(19,496)

(38,324)

Other (expense) income

(Loss) gain on sale of assets

(1,627)

90

900

90

Other (expense) income

1,205

(200)

10,255

(249)

Foreign currency loss

30

(403)

(108)

(778)

Interest expense

(12,311)

(2,439)

(19,350)

(3,214)

Contract asset impairment

(2,420)

(2,420)

Loss before taxes and non-controlling interest

(14,319)

(24,447)

(30,219)

(42,475)

Income taxes

(1,132)

(1,637)

(4,926)

(4,035)

Loss from continuing operations before non-controlling interest

(15,451)

(26,084)

(35,145)

(46,510)

Net loss from discontinued operations, net of tax

(905)

(1,289)

Net loss before non-controlling interest

(16,356)

(26,084)

(36,434)

(46,510)

(Loss) gain attributed to non-controlling interest

(1,929)

590

(1,841)

968

Net loss attributed to Harvest Health & Recreation Inc.

$

(18,285)

$

(25,494)

$

(38,275)

$

(45,542)

Loss per share – basic and diluted

$

(0.05)

$

(0.09)

$

(0.11)

$

(0.16)

Attributable to Harvest Health and Recreation Inc. Stockholders

$

(0.04)

$

(0.09)

$

(0.11)

$

(0.16)

Attributable to non-controlling interest

$

(0.01)

$

0.00

$

(0.01)

$

0.00

Weighted-average shares outstanding – basic and diluted

364,580,737

285,071,254

334,380,082

284,690,893

Non-IFRS Financial and Performance Measures

The Company provides additional financial metrics that are not prepared in accordance with IFRS. Management uses non-IFRS financial measures, in addition to IFRS financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate the Company’s financial performance. This non-IFRS financial measure is Adjusted EBITDA.

Management believes that these non-IFRS financial measures reflect the Company’s ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as they facilitate comparing financial results across accounting periods and to those of peer companies. Management also believes that these non-IFRS financial measures enable investors to evaluate the Company’s operating results and future prospects in the same manner as management. These non-IFRS financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company’s ongoing operating results.

As there are no standardized methods of calculating these non-IFRS measures, the Company’s methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

Reconciliations of Non-IFRS Financial and Performance Measures

The table below reconciles Net Loss to Adjusted EBITDA for the periods indicated.

Three months ended June 30,

Six months ended June 30,

2020

2019

2020

2019

Net loss (IFRS) before non-controlling interest

$

(16,356)

$

(26,084)

$

(36,434)

$

(46,510)

Add (deduct) impact of:

Net interest and other financing costs (1)

12,532

2,961

19,737

3,736

Income tax

1,132

1,637

4,926

4,035

Amortization and depreciation (2)

4,599

2,130

8,840

4,206

(Gain) loss on assets

1,627

(90)

(900)

(90)

Other (expense) income

(1,205)

200

(10,255)

249

Foreign currency loss

(30)

403

108

778

Share-based compensation expense

3,276

8,094

17,080

11,397

Contract asset impairment

2,420

2,420

Discontinued operations, net of tax

905

1,289

Realized fair value amounts included in inventory sold

20,134

7,740

29,227

13,475

Unrealized fair value gain on growth of biological assets

(27,055)

(13,075)

(39,873)

(18,847)

Other expansion expenses (pre-open)

1,203

1,365

2,926

2,495

Transaction & other special charges

955

2,336

1,402

7,956

Adjusted EBITDA (non-IFRS)

$

4,137

$

(12,383)

$

493

$

(17,120)

(1) Includes $221, $522, $387 and $522 of interest reported in cost of sales.

(2) Includes $1,079, $530, $1,863 and $1,113 of depreciation reported in cost of sales. 

About Harvest Health & Recreation Inc.

Headquartered in Tempe, Arizona, Harvest Health & Recreation Inc. is a vertically integrated cannabis company and multi-state operator. Since 2011, Harvest has been committed to expanding its retail and wholesale presence throughout the U.S., acquiring, manufacturing, and selling cannabis products for patients and consumers in addition to providing services to retail dispensaries. Through organic license wins, service agreements, and targeted acquisitions, Harvest has assembled an operational footprint spanning multiple states in the U.S. Harvest’s mission is to improve lives through the goodness of cannabis. We hope you’ll join us on our journey: https://harvesthoc.com 

Facebook: @HarvestHOC 
Instagram: @HarvestHOC 
Twitter: @HarvestHOC

Forward-looking Statements

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Harvest with respect to future business activities. Forward-looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) expectations regarding the size of the U.S. cannabis market, (ii) the ability of the Company to successfully achieve its business objectives, (iii) plans for expansion of Harvest, and (iv) expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects Harvest management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Harvest believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the effects of the weather, natural disasters, and health pandemics, including the novel coronavirus (COVID-19), on customer demand, the Company’s supply chain as well as its consolidated results of operation, financial position and cash flows, the ability of Harvest to open additional retail locations and meet its revenue growth and profitability objectives, the ability of Harvest to integrate recent acquisitions, the ability of Harvest to obtain and/or maintain licenses or other contractual rights to operate in the jurisdictions in which it operates or in which it expects or plans to operate; changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of Harvest to raise debt and equity capital in the amounts needed and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that Harvest operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws, including those related to taxation; and increasing costs of compliance with extensive government regulation. This forward-looking information may be affected by risks and uncertainties in the business of Harvest and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Harvest has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Harvest does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Additional Information

The financial information reported in this news release is based on unaudited management prepared financial statements for the quarter ended June 30, 2020. Accordingly, such financial information may be subject to change. Financial statements for the period will be released and filed under the Company’s profiles on SEDAR at www.SEDAR.com by August 28, 2020. All financial information contained in this news release is qualified in its entirety with reference to such unaudited financial statements. While the Company does not expect there to be any material changes, to the extent that the financial information contained in this news release is inconsistent with the information contained in the Company’s unaudited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company’s unaudited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/harvest-health–recreation-inc-reports-second-quarter-2020-financial-results-301110269.html

SOURCE Harvest Health & Recreation Inc.

Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2020/11/c0331.html

Source: news.yahoo.com


Global Luxury Bag Market 2020 - Growth Factors, Top Manufacturers, Future Investment, Segmentation, Share, Size, CAGR, Latest Trends, Forecast 2025

Global Luxury Bag Market 2020 – Growth Factors, Top Manufacturers, Future Investment, Segmentation, Share, Size, CAGR, Latest Trends, Forecast 2025

Global Luxury Bag Market Report Focuses on Industry chain structure, Production Capacity, Overall Revenue and Market share of each Manufacturer. This Analytical Report offers wide-range of Insights into the Development Policies, Plans, Cost structure and Technical Data. Also, The Luxury Bag Market Report offers a perfect understanding of Proposal for New Investments and Projects, Business Strategy and the subject matter.

Final Report will add the analysis of the impact of COVID-19 on this Industry.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT – REQUEST SAMPLE

Scope of the Luxury Bag Market Report:

Luxury Bag is pleasant to have but is not necessary. Compared with general bag, the Luxury bag is more expensive. Luxury bag are generally more than a few hundred dollars.

The global Luxury Bag Sales market research report 2017 is a professional and in-depth study on the current state of the Luxury Bag market.

Firstly, the report provides a basic overview of the market including definitions, classifications, applications and market chain structure. The Luxury Bag market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status.

Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin by regions (USA, Europe, China and Japan), and other regions can be added.

Then, the report focuses on global major leading market players with information such as company profiles, product picture, price, revenue and contact information. Upstream raw materials, and downstream consumers analysis is also carried out. What’s more, the Luxury Bag Sales market development trends and marketing channels are analyzed.

In a word, the report provides major statistics on the state of the market and is a valuable source of guidance and direction for companies and individuals interested in the market.

The global Luxury Bag market is valued at 50600 million USD in 2018 and will reach 92900 million USD by the end of 2025, growing at a CAGR of 7.9% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Luxury Bag market based on company, product type, end user and key regions.

This report studies the global market size of Luxury Bag in key regions like North America, Europe, Asia Pacific, Central and South America and Middle East and Africa, focuses on the consumption of Luxury Bag in these regions.

This research report categorizes the global Luxury Bag market by top players/brands, region, type and end user. This report also studies the global Luxury Bag market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast periodto estimate the market size for Luxury Bag. This report researches the worldwide Luxury Bag market size (value, capacity, production and consumption) in key regions likeUnited States, Europe, Asia Pacific (China, Japan) and other regions.

Get Sample PDF of report -https://www.360marketupdates.com/enquiry/request-sample/13652700

Luxury Bag MarketSegment byProductTypesconsidering Production, Revenue (Value), Price Trends:

Market Segment byApplicationsconsidering Consumption Growth Rate and Market Share:

Major Key Playersof Luxury Bag Market Report:

Feel Free to Ask Question Before Purchasing the Report at -https://www.360marketupdates.com/enquiry/pre-order-enquiry/13652700

Furtherin the Luxury Bag Market research reports,followingpoints are included along within-depthstudy of each point:

Luxury BagMarket Report Includes:

Benefits of Purchasing Luxury Bag Market Report:

Purchase this report (Price 3900 USD for a single-user license) -https://www.360marketupdates.com/purchase/13652700

Table of Contents

1 Study Coverage

2 Executive Summary

3 Breakdown Data by Manufacturers

4 Breakdown Data by Type

5 Breakdown Data by Application

6 North America Luxury Bag Market by Countries

7 Europe Luxury Bag Market by Countries

8 Asia Pacific Luxury Bag Market by Countries

9 Central and South America Luxury Bag Market by Countries

10 Middle East and Africa Luxury Bag Market by Countries

11 Company Profiles

12 Future Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

14 Value Chain and Sales ChannelsAnalysis and many more

Be sure to follow us on Linkedin at @360 Market Updatesfor more on growth research and the research market.

Contact Us:

Name: Mr. Ajay More

Email: sales@360marketupdates.com

Organization: 360 Market Updates

Phone: +44 20 3239 8187/ +1 424 253 0807

OUR OTHER REPORTS:- AAA

Automotive Oil Pressure Control Valves Market 2020 – Global Industry Growth Rate, Share, Size, Price, Prospect, Developments and Forecast till 2026

Global Angiography Device Market Size 2020 – Current Industry Status, Share, CAGR, Growth Rate and Forecast till 2025

Motorhomes Market 2020 – Impact of Covid 19 on Industry Share, Size, Price, CAGR, Growth Rate and Future Prospects

Yellow Oyster Mushroom Market Report 2020 – Indepth Analysis on Market Share, Size, Growth Rate and Factors, Future Developments and Prospects

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Global Luxury Bag Market 2020 – Growth Factors, Top Manufacturers, Future Investment, Segmentation, Share, Size, CAGR, Latest Trends, Forecast 2025

COMTEX_369204810/2598/2020-08-11T01:28:58

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Source: www.marketwatch.com


It's Now Time for iBio to Deliver the Goods

It’s Now Time for iBio to Deliver the Goods

iBio (NYSEAMERICAN:IBIO) is the third (or maybe the fourth) “vaccine stock” I’ve written about in the last week or so. And there’s good reason the company has the attention of investors. Since July, IBIO stock is up nearly 83%. But that’s just pocket change from the 1,166% gain the stock has made in 2020.

A scientist in medical gear peers through a microscope.

That’s not a misprint. IBIO stock traded at 30 cents a share at the start of the year. As of the market close on August 7, iBio was trading for $3.80. And there are conflicting opinions about whether the high flier has room to go even higher.

The novel coronavirus remains a vexing threat to our public health and our economy. So it’s logical that investors are focused on the progress toward the goal of a vaccine. iBio is one of dozens of companies trying to develop a Covid-19 vaccine. But for iBio, the method they are using to develop a vaccine, and bring a successful candidate to scale is what has held investors’ attention. However, that same technology is what continues to make the stock a speculative play at best.

iBio’s FastPharming technology may truly revolutionize the industry, but for right now, it needs a proof of concept that is slow to develop.

It’s becoming apparent that there will be multiple successful vaccine candidates for the novel coronavirus. And iBio is working with scientists at Texas A&M University to develop two separate vaccine candidates.

The company’s most recent vaccine candidate, IBIO-201 fuses antigens from the virus’ spike protein with iBio’s patented lichenase booster molecule (LicKM). According to the company’s internal documents, adding the LicKM booster to a subunit antigen offers two benefits. First, it’s expected to improve the likelihood of achieving single-dose, prolonged immunity. And second, it should allow increased manufacturing capacity through increased potency.

However, the speed at which other companies are getting their vaccine candidates moving through the clinical trial phase is making iBio’s chances of being successful a long shot.

As I mentioned in my prior article on iBio, the company has a proprietary manufacturing platform, FastPharming, which may allow it to assist in bringing vaccine candidates from other companies to scale.

FastPharming is a plant-based process to develop antibodies, other therapeutic proteins and vaccines. By using plants as bioreactors, FastPharming can allow iBio to bypass the traditionally expensive, labor-intensive, cell-line development. This means, in theory, a vaccine could be scaled very quickly. The only requirement is to grow more plants.

That’s the good news. The troublesome news is that, as it relates to a Covid-19 vaccine, none of the leading competitors are signing up with iBio to use their process. Muslim Farooque wrote about how companies with vaccine candidates that are further into clinical trials, such as Moderna (NASDAQ:MRNA), are finding partners to scale up production. Farooque writes, “That makes it imperative for iBio to make some consequential moves now before it loses out on significant contracts.”

I believe some of this is simply due to the idea that the technology, while oozing with potential, is unproven. And when the stakes are as high as they are with Covid-19, nobody wants to be iBio’s proof of concept.

That’s not to discount iBio’s long-term potential. IBIO stock received a boost in late July when it announced a partnership with Brazil-based vaccine manufacturer Bio-Manguinhos/Fiocruz. For its part, Bio-Manguinhos/Fiocruz will invest more than $6 million to bring a new yellow fever vaccine through Phase I clinical trials based on iBio’s green plant production method.

The two companies will then work together to develop the product with IBio’s research and development collaborator, the Fraunhofer USA Center for Molecular Biotechnology (FCMB).

I understand the speculative bet on IBIO stock. It was a penny stock to start the year. And despite its phenomenal growth this year, it’s still a penny stock. If, and that’s a big if, the company can become a viable player in the development of a vaccine, the stock could go much higher.

But if the company is not included in the production of a vaccine, then this stock will remain just a story. Plant-based materials are becoming a part of our daily lives. And maybe that will be the case for iBio.

But that’s not a guarantee when it comes to something like vaccine development. Right now, the companies that are in Phase 3 trials are looking to go down other paths. And that means when it comes to IBIO stock, you would be advised to do the same.

Chris Markoch is a freelance financial copywriter who has been covering the market for over five years. He has been writing for Investor Place since 2019. As of this writing, Chris Markoch did not hold a position in any of the aforementioned securities.

Source: investorplace.com

Author: By Chris Markoch

Aug 11, 2020, 7:55 am EDT

August 10, 2020


Kodak insider's stock donation raises new concerns around the company's government loan

Kodak insider’s stock donation raises new concerns around the company’s government loan

After news of a massive federal loan caused Eastman Kodak’s stock to skyrocket, a company insider donated millions of shares to a religious nonprofit for which he has served as president.

On July 29, the peak of Kodak’s recent 2,757% stock surge, a member of the company’s board of directors, George Karfunkel, and his wife donated 3 million shares of Kodak stock — valued at more than $100 million at the time — to a synagogue called Congregation Chemdas Yisroel Inc., according to a securities filing. The synagogue is registered as a charity in New York state.

The donation, which could potentially be claimed as a tax deduction, came in the midst of heavy trading of Kodak’s stock that was sparked by the news that the company would receive a $765 million loan from the US government to help make drug ingredients.

The timing of the announcement and the issuance of certain executives’ stock options have prompted federal scrutiny. House Democrats requested documents and information on the matter from Kodak, according to a letter sent last week.

The Securities and Exchange Commission is reportedly investigating the circumstances around Kodak’s announcement of the loan, according to the Wall Street Journal.

The Journal and Mother Jones first reported Karfunkel’s donation.

Kodak said in a securities filing Friday that an internal review conducted by an external law firm will examine activity connected to the potential loan. The company said a special committee of independent directors would oversee the internal review.

A spokesperson for Kodak told CNN that donation by the Karfunkels is “within the scope” of that review. The Karfunkels could not be reached for comment.

Kodak’s website describes George Karfunkel as an expert in financial planning and investment strategy who has served on the company’s board of directors since 2013.

The day of his and his wife’s donation, Kodak’s stock hit a low of $17.50 a share and a high of $60, meaning the donation could be worth more than $100 million.

On Friday, the agency behind the loan said that the deal would be put on hold. “Recent allegations of wrongdoing raise serious concerns,” the US International Development Finance Corporation tweeted. “We will not proceed any further unless these allegations are cleared.”

On Monday, Kodak’s stock was temporarily halted after plunging as much as 43% earlier in the day.

Laurie Styron, the executive director of the nonprofit CharityWatch, described the situation involving Karfunkel’s donation as concerning. His position on Kodak’s board may have given him “special knowledge that allowed him to predict likely fluctuations in Kodak’s stock price,” she said.

She also said many charities and religious organizations that offer tax deductions have controls in place to prevent the appearance of impropriety.

“With Karfunkel having one foot firmly planted in both Kodak and in the religious organization receiving the stock donation, it’s unclear if enough board independence existed for this donation to be properly vetted and approved at arm’s length prior to being accepted,” Styron said.

New York charity filings from 2019 describe Congregation Chemdas Yisroel as an Orthodox Jewish synagogue that uses funds exclusively for religious, charitable and educational purposes. The documents list George Karfunkel as the congregation’s president.

Representatives for Congregation Chemdas Yisroel could not be reached for comment.

Source: keyt.com

Author: By CNN


How major US stock indexes fared Tuesday

How major US stock indexes fared Tuesday

A late slide in big technology companies left indexes broadly lower on Wall Street Tuesday, erasing an early gain and breaking a seven-day winning streak for the S&P 500

ABC News

Source: abcnews.go.com

Author: ABC News


Harvest Health & Recreation Inc. Reports Second Quarter 2020 Financial Results


Leave a Comment